elasomeran
AssetAlso mRNA-1273, CX-024414, M-1273, TAK-919
Encodes SARS-CoV-2 spike protein to induce protective immune responses against COVID-19.
- Stage
- Approved
- Modality
- mRNA
- Target
- S
- 6
- Indications
- 24
- Trials
- 2
- Developers
Indications
6COVID-19
Approved, doi.org, Aug 4, 2024
Sars cov 2
Phase 3, Recruiting, NCT07863635, clinicaltrials.gov, Oct 28, 2026
Cytomegalovirus
Phase 1, Completed, NCT05397223, clinicaltrials.gov, Oct 29, 2026
3 more
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials24
- Evidence for its targets2
- Competitors8
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.